AstraZeneca (AZN.L)
A global biopharmaceutical leader specializing in high-impact therapeutic areas like oncology, rare diseases, and cardiovascular medicine.
What AstraZeneca does
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company operates primarily in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal, metabolism, and respiratory and immunology areas.
Themes: oncology / cancer research, rare diseases, cardiovascular disease therapy, respiratory medicine, biopharmaceuticals
Fundamentals
- Price£115.00 as of 2026-08-03 close
- Market capn/a company fundamentals are not available for UK-listed companies in our data
- 1-year return+3.6% 2025-08-01 close £111.04 → 2026-08-03 close £115.00
- P/En/a company fundamentals are not available for UK-listed companies in our data
- Net marginn/a company fundamentals are not available for UK-listed companies in our data
- Gross marginn/a company fundamentals are not available for UK-listed companies in our data
- ROEn/a company fundamentals are not available for UK-listed companies in our data
- Debt / equityn/a company fundamentals are not available for UK-listed companies in our data
- Revenue growth (YoY)n/a company fundamentals are not available for UK-listed companies in our data
- Revenue CAGR (3y)n/a company fundamentals are not available for UK-listed companies in our data
- Betan/a we do not track a market benchmark for UK-listed companies
Dividend: company fundamentals are not available for UK-listed companies in our data.
How AstraZeneca looks technically
AstraZeneca (AZN.L) is trading 15.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 9 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 29, in oversold territory (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It just made a new 20-day low, its first since 2025-09-30, breaking below its recent trading range. It is 26.9% below its highest point of the past year. Trading volume is unusually light — only about 0% of its 30-day average.
Trend
| Distance from the 200-day | -15.3% | it is trading 15.3% below its 200-day average, the long-term trend line — a long-term downtrend |
|---|---|---|
| 50-day moving average | £133.32 | its average price over the last 50 trading days — a short-term trend line — is £133.32 |
| 200-day moving average | £135.76 | its average price over the last 200 trading days — the long-term trend line — is £135.76 |
| Since the 50/200 cross | 9 sessions | its 50-day average crossed below its 200-day average about 9 trading days ago — a "death cross", a bearish long-term signal |
| Trend strength (14-day ADX) | 37.5 | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with sellers in control |
Momentum
| 14-day RSI | 29.0 | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 29, in oversold territory (below 30) |
|---|---|---|
| Since the MACD crossed zero | 1 session | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) |
Range
| 52-week high | £157.32 | its highest closing price over the past year (about 252 trading days) was £157.32 |
|---|---|---|
| From the 52-week high | -26.9% | it is 26.9% below its 52-week high (its highest price of the past year) |
| Above the 52-week low | +16.3% | it is 16.3% above its 52-week low (its lowest price of the past year) |
| Below the 52-week high | 26.9% | it is 26.9% below its highest point of the past year |
| Since a 20-day breakout | 1 session | it just made a new 20-day low, its first since 2025-09-30, breaking below its recent trading range |
| Since a 55-day breakout | 1 session | it just made a new 55-day low, its first since 2025-09-30, breaking below its recent trading range |
| All-time high | £157.32 | its highest closing price on record is £157.32 (set on 2026-02-18) |
| From the all-time high | -26.9% | it is 26.9% below its all-time high |
| All-time low | £1.04 | its lowest closing price on record is £1.04 (set on 2023-10-25) |
| Above the all-time low | +10,988% | it is 10987.5% above its all-time low |
Volatility
| Band width vs its own 6 months | 83rd percentile | day-to-day price swings are unusually wide versus its own recent history (wider than about 83% of the past ~6 months) |
|---|---|---|
| Bollinger bands (20-day, ±2σ) | £116.03 – £128.15 – £140.27 | most of its recent trading has stayed between about £116.03 and £140.27 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles |
Volume
| Volume vs its 30-day average | 0.00× | trading volume is unusually light — only about 0% of its 30-day average |
|---|
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-03. Describes past price behavior only — informational, not financial advice.
Key risks (from latest filing)
["high dependency on the success of clinical trials and regulatory approvals","patent expirations and the threat of generic or biosimilar competition","exposure to volatile global healthcare pricing and reimbursement policies"]
Competitors & peers
- Pfizer (PFE)
- Roche (RHHBY)
- Merck & Co. (MRK)
- Bristol Myers Squibb (BMY)
- Novartis (NVS)
- Sanofi (SNY)
- GlaxoSmithKline (GSK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AZN.L vs…
Frequently asked questions
What does AstraZeneca (AZN.L) do?
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company operates primarily in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal, metabolism, and respiratory and immunology areas.
Who are AstraZeneca's (AZN.L) competitors?
Notable peers of AstraZeneca (AZN.L) include Pfizer, Roche, Merck & Co., Bristol Myers Squibb and Novartis. This peer set is informational only — not financial advice.
Is AstraZeneca (AZN.L) overbought or oversold right now?
AstraZeneca (AZN.L) is currently in oversold territory (its 14-day RSI is 29, below 30) (as of 2026-08-03). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AZN.L come from?
Fundamentals and prices come from market data. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from market data, shown with their as-of date.